Literature DB >> 22240200

TET2, a tumor suppressor in hematological disorders.

Thomas Mercher1, Cyril Quivoron, Lucile Couronné, Christian Bastard, William Vainchenker, Olivier A Bernard.   

Abstract

The TET family of proteins has been described a few years ago. Only recently, their roles in DNA modification, through the oxidation of methyl-cytosine, and in normal and malignant development, through the description of TET2 as a tumor suppressor have been documented. The conjunction of these findings has prompted large efforts to understand the biology of these novel entities. Here, we summarize the recent results implicating TET2 in hematological malignancies suggesting that further studies are required to fully understand the role of DNA methylation alterations during transformation. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22240200     DOI: 10.1016/j.bbcan.2011.12.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  TETonic shift: biological roles of TET proteins in DNA demethylation and transcription.

Authors:  William A Pastor; L Aravind; Anjana Rao
Journal:  Nat Rev Mol Cell Biol       Date:  2013-06       Impact factor: 94.444

2.  Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability.

Authors:  Suhas S Kharat; Xia Ding; Divya Swaminathan; Akshey Suresh; Manish Singh; Satheesh K Sengodan; Sandra Burkett; Hanna Marks; Chinmayi Pamala; Yafeng He; Stephen D Fox; Eugen C Buehler; Kathrin Muegge; Scott E Martin; Shyam K Sharan
Journal:  Sci Signal       Date:  2020-08-18       Impact factor: 8.192

Review 3.  TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics.

Authors:  Yihong Guan; Metis Hasipek; Anand D Tiwari; Jaroslaw P Maciejewski; Babal K Jha
Journal:  Semin Hematol       Date:  2020-12-28       Impact factor: 3.851

Review 4.  Myeloid malignancies: mutations, models and management.

Authors:  Anne Murati; Mandy Brecqueville; Raynier Devillier; Marie-Joelle Mozziconacci; Véronique Gelsi-Boyer; Daniel Birnbaum
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430

5.  Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications.

Authors:  Hernando Lopez-Bertoni; Amanda Johnson; Yuan Rui; Bachchu Lal; Sophie Sall; Maureen Malloy; Jonathan B Coulter; Maria Lugo-Fagundo; Sweta Shudir; Harmon Khela; Christopher Caputo; Jordan J Green; John Laterra
Journal:  Signal Transduct Target Ther       Date:  2022-02-09

Review 6.  The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).

Authors:  Helen Ma; Ardy Davarifar; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 4.213

7.  Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia.

Authors:  Lucila H Oliveira; Josiane L Schiavinato; Mariane S Fráguas; Antonio R Lucena-Araujo; Rodrigo Haddad; Amélia G Araújo; Leandro F Dalmazzo; Eduardo M Rego; Dimas T Covas; Marco A Zago; Rodrigo A Panepucci
Journal:  Cancer Sci       Date:  2015-09-21       Impact factor: 6.716

8.  Poly(ADP-ribosyl)ation is involved in the epigenetic control of TET1 gene transcription.

Authors:  Fabio Ciccarone; Elisabetta Valentini; Maria Giulia Bacalini; Michele Zampieri; Roberta Calabrese; Tiziana Guastafierro; Germano Mariano; Anna Reale; Claudio Franceschi; Paola Caiafa
Journal:  Oncotarget       Date:  2014-11-15

9.  Epigenetic dysregulation of TET2 in human glioblastoma.

Authors:  María G García; Antonella Carella; Rocío G Urdinguio; Gustavo F Bayón; Virginia Lopez; Juan Ramón Tejedor; Marta I Sierra; Estela García-Toraño; Pablo Santamarina; Raúl F Perez; Cristina Mangas; Aurora Astudillo; M Daniela Corte-Torres; Inés Sáenz-de-Santa-María; María-Dolores Chiara; Agustín F Fernández; Mario F Fraga
Journal:  Oncotarget       Date:  2018-05-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.